Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > Re....Re....Re........
View:
Post by ISAloser247 on Mar 01, 2010 6:49pm

Re....Re....Re........




       Hi BioMaster....,     I pulled the trigger on ISA years ago, shooting blanks made with BRE-X mined plating, still in daily pain.
       Any word on the Psoriasis front, or Transplantation .   I know that due to the financial circumstances of ISA somethings have been put on hold,  but what is actually going on?  Were not the trials finished in mid 2009?
There were presentations at Dermatological gatherings and yet ....nothing.  Was not the market for Transplantaion
drugs in the $ 4 billion range, as ALL ISA's propaganda states,  was not the Phase III trial successly completed?

     Roche put in 75 million, and walked away!  1.6 ?  Sincerely?
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities